Drug Description in Trials / DrugBank / KEGG DRUG


Search results


No. 薬物名(臨床試験情報から抽出) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1J01GB01----1件: 299 💬
2J05A F01----1件: 135 💬
3J05AG04----1件: 18 💬
4J07AH07----1件: 14 💬
5J1081----1件: 56 💬
6J695----1件: 96 💬
7J695, BSF 415977 (formerly LU415977), WAY-165772, A-796874.0----1件: 96 💬
8JAK 3----1件: 46 💬
9JAK 3 Ritlecitinib----1件: 46 💬
10JAK inhibitor----2件: 46, 50 💬
11JAK1 / JAK2 Inhibitor----1件: 46 💬
12JAK1 / JAK2 Inhibtor----1件: 46 💬
13JAKi----1件: 46 💬
14Jaktinib Dihydrochloride Monohydrate 50mg BID and Mimic tablets of jakitinib hydrochloride 75mg BID and Acetylcysteine Effervescent Tablets1件: Acetylcysteine1件: Acetylcysteine 💬--1件: 85 💬
15Jaktinib Dihydrochloride Monohydrate 75mg BID and Mimic tablets of jakitinib hydrochloride 50mg BID and Acetylcysteine Effervescent Tablets1件: Acetylcysteine1件: Acetylcysteine 💬--1件: 85 💬
16Jaktinib Hydrochloride Tablets----1件: 271 💬
17Janus Kinase Inhibitor----2件: 46, 97 💬
18Jardiance1件: Empagliflozin1件: Empagliflozin 💬1件: SLC5A2 💬-1件: 65 💬
19JBT-101----4件: 49, 50, 51, 299 💬
20JBT-101 (lenabasum)----1件: 299 💬
21JBT101----1件: 299 💬
22Jevity 1.0----1件: 2 💬
23Jevity 1.5----1件: 2 💬
24JHL1101----1件: 46 💬
25Jianpixiaozhong particles and Wuse Dietotherapy----1件: 222 💬
26Jinarc1件: Tolvaptan1件: Tolvaptan 💬1件: AVPR2 💬3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬1件: 67 💬
27JINARC - 15 MG +45 MG - COMPRESSA - USO ORALE - BLISTER(ALU/PVC) IN CONFEZIONE A PORTAFOGLIO - 56 COMPRESSE (28X15 MG + 28 X 45 MG)1件: Tolvaptan1件: Tolvaptan 💬1件: AVPR2 💬3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬1件: 67 💬
28JINARC - 15 MG - COMPRESSA - USO ORALE - BLISTER (ALU/PVC) - 28 COMPRESSE1件: Tolvaptan1件: Tolvaptan 💬1件: AVPR2 💬3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬1件: 67 💬
29JINARC - 30 MG + 60 MG - COMPRESSA - USO ORALE - BLISTER(ALU/PVC) IN CONFEZIONE A PORTAFOGLIO - 56 COMPRESSE (28 X 30 MG + 28 X 60 MG)1件: Tolvaptan1件: Tolvaptan 💬1件: AVPR2 💬3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬1件: 67 💬
30JINARC - 30 MG +90 MG - COMPRESSA - USO ORALE - BLISTER(ALU/PVC) IN CONFEZIONE A PORTAFOGLIO - 56 COMPRESSE (28 X 30 MG + 28 X 90 MG)1件: Tolvaptan1件: Tolvaptan 💬1件: AVPR2 💬3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬1件: 67 💬
31JINARC - 30 MG - COMPRESSA - USO ORALE - BLISTER (ALU/PVC) - 28 COMPRESSE1件: Tolvaptan1件: Tolvaptan 💬1件: AVPR2 💬3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬1件: 67 💬
32Jinarc - Tolvaptan tablets1件: Tolvaptan1件: Tolvaptan 💬1件: AVPR2 💬3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬1件: 67 💬
33Jinarc 15 mg tablets, Jinarc 45 mg tablets1件: Tolvaptan1件: Tolvaptan 💬1件: AVPR2 💬3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬1件: 67 💬
34Jinarc 30 mg Tablet1件: Tolvaptan1件: Tolvaptan 💬1件: AVPR2 💬3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬1件: 67 💬
35Jinarc 30 mg tablets, 90 mg tablets1件: Tolvaptan1件: Tolvaptan 💬1件: AVPR2 💬3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬1件: 67 💬
36Jinarc 30 mg tablets, Jinarc 60 mg tablets1件: Tolvaptan1件: Tolvaptan 💬1件: AVPR2 💬3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬1件: 67 💬
37Jinarc® 15mg Tablet1件: Tolvaptan1件: Tolvaptan 💬1件: AVPR2 💬3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬1件: 67 💬
38Jinarc® 30 Tablet1件: Tolvaptan1件: Tolvaptan 💬1件: AVPR2 💬3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬1件: 67 💬
39Jintropin AQ----1件: 78 💬
40JKB-122----1件: 95 💬
41JKB-122 in capsule or tablet form----1件: 95 💬
42JM----2件: 6, 13 💬
43JM-010----1件: 6 💬
44JM-4----1件: 13 💬
45JNJ 38518168----1件: 46 💬
46JnJ 54767414----1件: 28 💬
47JNJ-16240159-AAC----1件: 46 💬
48JNJ-31001074----1件: 6 💬
49JNJ-38518168----1件: 46 💬
50JNJ-38518168 (10 mg)----1件: 46 💬
51JNJ-38518168 (3 mg)----1件: 46 💬
52JNJ-38518168 (30 mg)----1件: 46 💬
53JNJ-38518168 / MTX----1件: 46 💬
54JNJ-38518168 50-mg Over Encapsulated Tablet----1件: 46 💬
55JNJ-38518168-AEK - Over Encapsulated Tablet - 50 mg----1件: 46 💬
56JNJ-38518168-ZBQ----1件: 46 💬
57JNJ-38518168-ZBQ - film-coated tablet - 10 mg----1件: 46 💬
58JNJ-38518168-ZBQ - film-coated tablet - 10mg----1件: 46 💬
59JNJ-38518168-ZBQ - film-coated tablet - 3 mg----1件: 46 💬
60JNJ-38518168-ZBQ - film-coated tablet - 30 mg----1件: 46 💬
61JNJ-38518168-ZBQ - film-coated tablet - 30mg----1件: 46 💬
62JNJ-38518168-ZBQ - film-coated tablet - 3mg----1件: 46 💬
63JNJ-39039039----1件: 210 💬
64JNJ-39758979----1件: 46 💬
65JNJ-39758979 (10 mg)----1件: 46 💬
66JNJ-39758979 (100 mg)----1件: 46 💬
67JNJ-39758979 (30 mg)----1件: 46 💬
68JNJ-39758979 (300 mg)----1件: 46 💬
69JNJ-39758979 / MTX----1件: 46 💬
70JNJ-39758979-AAC - enteric coated tablet - 10 mg----1件: 46 💬
71JNJ-39758979-AAC - enteric coated tablet - 100 mg----1件: 46 💬
72JNJ-39758979-AAC - enteric coated tablet - 30 mg----1件: 46 💬
73JNJ-403465271件: JNJ-40346527---2件: 46, 96 💬
74JNJ-40346527-AAC1件: JNJ-40346527---1件: 96 💬
75JNJ-40346527-AAC - capsule - 50 mg1件: JNJ-40346527---1件: 46 💬
76JNJ-42160443----1件: 226 💬
77JNJ-54767414----2件: 28, 49 💬
78JNJ-54781532 150 mg once daily----1件: 97 💬
79JNJ-54781532 25 mg once daily----1件: 97 💬
80JNJ-54781532 75 mg once daily----1件: 97 💬
81JNJ-54781532 75 mg twice daily----1件: 97 💬
82JNJ-54781532-AAD-10 mg----1件: 97 💬
83JNJ-54781532-AAD-30 mg----1件: 97 💬
84JNJ-54781532-AAD-5 mg----1件: 97 💬
85JNJ-55920839----1件: 49 💬
86JNJ-56022473----1件: 49 💬
87JNJ-64304500----1件: 96 💬
88JNJ-64304500-AAA----1件: 96 💬
89JNJ-64841829----1件: 97 💬
90JNJ-64841842----1件: 97 💬
91JNJ-64841855----1件: 97 💬
92JNJ-64841894----1件: 97 💬
93JNJ-64841907----1件: 97 💬
94JNJ-64841920----1件: 97 💬
95JNJ-64841933----1件: 97 💬
96JNJ-64841946----1件: 97 💬
97JNJ-66525433----1件: 97 💬
98JNJ-67484703----1件: 46 💬
99JNJ-67864238----1件: 96 💬
100JNJ-67896049----1件: 86 💬
101JNJ-67896049 (ACT-293987)----1件: 86 💬
102JNJ-67896062 / ACT-064992----2件: 86, 88 💬
103JNJ-67896062/ ACT-064992----2件: 86, 88 💬
104JNJ-67896062/ACT-064922----1件: 86 💬
105JNJ-67896153/ACT-128800----1件: 13 💬
106JNJ-72537634----1件: 97 💬
107JNJ-78934804----2件: 96, 97 💬
108JNJ-80202135----4件: 11, 46, 49, 53 💬
109JNJ31-31001074----1件: 6 💬
110Joint puncture----1件: 107 💬
111Jojoba oil1件: Jojoba oil---1件: 36 💬
112Jojoba oil with broccoli sprout extract2件: Broccoli,
Jojoba oil
---1件: 36 💬
113Jorveza1件: Budesonide1件: Budesonide 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
114Jorveza 0.5 mg compresse orodispersibili1件: Budesonide1件: Budesonide 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
115Jorveza 0.5 mg orodispersible tablets1件: Budesonide1件: Budesonide 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
116Jorveza 1 mg compresse orodispersibili1件: Budesonide1件: Budesonide 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
117Jorveza 1 mg orodispersible tablets1件: Budesonide1件: Budesonide 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
118JP 1730----1件: 6 💬
119JP-1730/F01----2件: 6, 17 💬
120JP-1730/F02----2件: 6, 17 💬
121JP-1730/F03----2件: 6, 17 💬
122JR-141----1件: 19 💬
123JR-141 or Idursulfase1件: Idursulfase1件: Idursulfase 💬1件: IDS 💬3件: Glycosaminoglycan degradation, Lysosome, Metabolic pathways 💬1件: 19 💬
124JR-171 (lepunafusp alfa)----1件: 19 💬
125JS002----1件: 79 💬
126JS005----1件: 271 💬
127JSP191----2件: 65, 285 💬
128JTE-051----1件: 46 💬
129JTT-251----1件: 86 💬
130Juanbi pill----1件: 46 💬
131Juvit D3----1件: 6 💬
132Jyseleca1件: Filgotinib1件: Filgotinib 💬1件: JAK1 💬27件: Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬1件: 46 💬
133Jyseleca 100 mg film-coated tablets1件: Filgotinib1件: Filgotinib 💬1件: JAK1 💬27件: Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬1件: 46 💬
134Jyseleca 200 mg film-coated tablets1件: Filgotinib1件: Filgotinib 💬1件: JAK1 💬27件: Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬1件: 46 💬
135JZP-110----1件: 6 💬